Table 2 Demographic and other baseline characteristics
Arm A | Arm B | Arm C | Arm D | Overall | ||
|---|---|---|---|---|---|---|
(N=60) | (N=64) | (N=58) | (N=59) | (N=241) | ||
Age (years) | ||||||
Median (Range) | 58.5 (37-76) | 57.5 (31-74) | 56 (38-77) | 55 (33-76) | 57 (31-77) | |
N (%) | N (%) | N (%) | N (%) | N (%) | ||
Ethnic Origin, N (%) | Caucasian | 58 (96.6) | 63 (98.4) | 58 (100) | 59 (100) | 238 (98.8) |
African | 1 (1.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (0.4) | |
Asian | 1 (1.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (0.4) | |
Othera | 0 (0.0) | 1 (1.6) | 0 (0.0) | 0 (0.0) | 1 (0.4) | |
Menopausal status, N (%) | pre | 19 (31.7) | 17 (26.6) | 16 (27.6) | 21 (35.6) | 73 (30.3) |
post | 41 (68.3) | 47 (73.4) | 42 (72.4) | 38 (64.4) | 168 (69.7) | |
Karnofsky Performance Status, N (%) | Point | |||||
Able to care for self | 70 | 0 (0.0) | 0 (0.0) | 2 (3.5) | 2 (3.4) | 4 (1.66) |
Normal activity but requiring effort | 80 | 5 (8.3) | 3 (4.7) | 5 (8.6) | 7 (11.9) | 20 (8.3) |
Able to carry on normal activity | 90 | 11 (18.3) | 16 (25.0) | 9 (15.5) | 15 (25.4) | 51 (21.2) |
Normal | 100 | 44 (73.3) | 44 (68.8) | 41 (70.7) | 35 (59.3) | 164 (68.0) |
Not done | 0 (0.0) | 1 (1.56) | 1 (1.72) | 0 (0.0) | 2 (0.8) | |
Hormonal receptor status, N (%) | ER+ | 44 (73.3) | 47 (73.4) | 39 (67.2) | 46 (78.0) | 176 (73.0) |
PR+ | 38 (63.3) | 43 (67.2) | 34 (58.6) | 42 (71.2) | 157 (65.1) | |
Previous hormonal therapy, N (%) | Yes | 44 (73.7) | 48 (75.0) | 40 (69.0) | 46 (78.0) | 178 (73.9) |
No | 16 (26.7) | 16 (25.0) | 17 (29.3) | 13 (22.0) | 62 (25.7) | |
Visceral metastases, N (%) | Absence | 19 (31.7) | 19 (29.7) | 16 (27.6) | 23 (39.0) | 77 (32.0) |
Presence | 41 (68.3) | 45 (70.3) | 42 (72.4) | 36 (61.0) | 164 (68.0 | |
Previous adjuvant/neoadjuvant taxane therapyb, N (%) | Yes | 21 (35.0) | 24 (37.5) | 12 (20.7) | 19 (32.2) | 76 (31.5) |
No | 39 (65.0) | 40 (62.5) | 45 (77.6) | 40 (67.8) | 164 (68.0) | |